Minglu Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minglu Zhou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Lian Li
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
3 shared publications - Yucheng Xiang
Sichuan Higher Education Institute Key Laboratory of Structure-Specific Small Molecule Drugs, Institute of Materia Medica, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China
3 shared publications - Jiaqi Fu
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
2 shared publications - Juan Yang
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
2 shared publications - Shenao Yan
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
2 shared publications - Zefan Liu
First People’s Hospital of Shuangliu District (West China Airport Hospital of Sichuan University), Chengdu 610200, China
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1376
Delivery Strategies Targeting Senescent Cells: From Precise Elimination to Functional Remodeling
The accumulation of senescent cells in tissues serves as a fundamental driver of aging and age-related pathologies, including chronic inflammation, tissue dysfunction, and organ degeneration. Conventional anti-aging interventions often suffer from limited specificity and off-target toxicity. Currently, developing therapeutic strategies capable of precisely targeting senescent cells is urgent. This review focuses on recent advances in delivery strategies designed to achieve either the selective elimination or functional modulation of senescent cells, with the goal of transitioning from broad-spectrum interventions to precision senotherapy. We systematically discuss the latest developments in senescence-targeting delivery platforms. To realize in vivo senescent-cell clearance, nanocarrier-based systems which are responsive to the senescent microenvironment and immune cell-based approaches are engineered. In parallel, we also reviewed emerging strategies for functional remodeling. Advanced delivery vehicles including lipid nanoparticles, extracellular vesicles, and engineered cell therapies are used to realize metabolic reprogramming and epigenetic modulation. The critical mechanisms of delivery systems in overcoming diverse barriers to improve specificity, bioavailability, and safety are highlighted. In this review, we aim to provide a preliminary framework that could serve as a useful reference for guiding the clinical translation of emerging senotherapies.
- 27 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1376
Open AccessDelivery Strategies Targeting Senescent Cells: From Precise Elimination to Functional Remodeling
The accumulation of senescent cells in tissues serves as a fundamental driver of aging and age-related pathologies, including chronic inflammation, tissue dysfunction, and organ degeneration. Conventional anti-aging interventions often suffer from limited specificity and off-target toxicity. Currently, developing therapeutic strategies capable of precisely targeting senescent cells is urgent. This review focuses on recent advances in delivery strategies designed to achieve either the selective elimination or functional modulation of senescent cells, with the goal of transitioning from broad-spectrum interventions to precision senotherapy. We systematically discuss the latest developments in senescence-targeting delivery platforms. To realize in vivo senescent-cell clearance, nanocarrier-based systems which are responsive to the senescent microenvironment and immune cell-based approaches are engineered. In parallel, we also reviewed emerging strategies for functional remodeling. Advanced delivery vehicles including lipid nanoparticles, extracellular vesicles, and engineered cell therapies are used to realize metabolic reprogramming and epigenetic modulation. The critical mechanisms of delivery systems in overcoming diverse barriers to improve specificity, bioavailability, and safety are highlighted. In this review, we aim to provide a preliminary framework that could serve as a useful reference for guiding the clinical translation of emerging senotherapies.
- Open Access
- 27 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1070
Advances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges
Nanodrug delivery systems have shown great promise against tumors, inflammatory diseases and central nervous system disorders. However, several limitations still exist before further clinical application. The unsatisfactory circulation time in vivo, rapid clearance by the mononuclear phagocyte system, insufficient tissue penetration and low targeting efficiency all hinder the clinical translation of nanomedicines. Cells are the fundamental functional units of the body and their intrinsic biological properties make them promising drug delivery vehicles for targeted therapy. Conjugating cells with nanomedicines combines the carrier functions of living cells with the therapeutic effects of nanodrugs, offering an effective strategy to improve targeted drug delivery. Compared with the existing literature, this review specifically summarizes the biological properties and major applications of six types of living cell carriers. The recent strategies for constructing cell–nanomedicine conjugates are also discussed. Finally, we highlight the current challenges for clinical translation and discuss future directions for the development of cell–nanomedicine delivery systems.
- 27 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1070
Open AccessAdvances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges
Nanodrug delivery systems have shown great promise against tumors, inflammatory diseases and central nervous system disorders. However, several limitations still exist before further clinical application. The unsatisfactory circulation time in vivo, rapid clearance by the mononuclear phagocyte system, insufficient tissue penetration and low targeting efficiency all hinder the clinical translation of nanomedicines. Cells are the fundamental functional units of the body and their intrinsic biological properties make them promising drug delivery vehicles for targeted therapy. Conjugating cells with nanomedicines combines the carrier functions of living cells with the therapeutic effects of nanodrugs, offering an effective strategy to improve targeted drug delivery. Compared with the existing literature, this review specifically summarizes the biological properties and major applications of six types of living cell carriers. The recent strategies for constructing cell–nanomedicine conjugates are also discussed. Finally, we highlight the current challenges for clinical translation and discuss future directions for the development of cell–nanomedicine delivery systems.
- Open Access
- 31 July 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (8) , 884
Recent Advances in Lipid Nanoparticle-Mediated Respiratory and Gastrointestinal Mucosal Delivery of Nucleic Acids
The clinical translation of nucleic acids is severely hindered by multiple delivery barriers, such as enzymatic degradation, poor cellular uptake, endosomal entrapment, and rapid systemic clearance. Despite the remarkable therapeutic potential of these agents, conventional delivery systems often fail to address these challenges. Lipid nanoparticles (LNPs) have emerged as a versatile platform to overcome these obstacles, offering tunable physicochemical properties, high encapsulation efficiency, and pH-responsive endosomal escape. This review summarizes recent advances in LNP-based respiratory and gastrointestinal mucosal delivery of nucleic acids, with emphasis on formulation strategies for overcoming mucus and epithelial barriers. To overcome mucosal barriers, LNP studies have shown that keeping particle size below the local mucus mesh size (~100 nm), tuning surface charge toward near-neutrality via pH-responsive ionizable lipids, and maintaining a neutral, deformable, moderately PEGylated surface during the mucin transport stage can increase transmucosal diffusivity several-fold over conventional cationic LNPs. We further discuss current limitations and propose future directions, emphasizing the need for the integration of the pathological and physiological characteristics of specific mucosa with artificial intelligence (AI) platforms to develop intelligent and personalized delivery platforms with “spatiotemporal adaptive” capabilities.
- 31 July 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (8) , 884
Open AccessRecent Advances in Lipid Nanoparticle-Mediated Respiratory and Gastrointestinal Mucosal Delivery of Nucleic Acids
The clinical translation of nucleic acids is severely hindered by multiple delivery barriers, such as enzymatic degradation, poor cellular uptake, endosomal entrapment, and rapid systemic clearance. Despite the remarkable therapeutic potential of these agents, conventional delivery systems often fail to address these challenges. Lipid nanoparticles (LNPs) have emerged as a versatile platform to overcome these obstacles, offering tunable physicochemical properties, high encapsulation efficiency, and pH-responsive endosomal escape. This review summarizes recent advances in LNP-based respiratory and gastrointestinal mucosal delivery of nucleic acids, with emphasis on formulation strategies for overcoming mucus and epithelial barriers. To overcome mucosal barriers, LNP studies have shown that keeping particle size below the local mucus mesh size (~100 nm), tuning surface charge toward near-neutrality via pH-responsive ionizable lipids, and maintaining a neutral, deformable, moderately PEGylated surface during the mucin transport stage can increase transmucosal diffusivity several-fold over conventional cationic LNPs. We further discuss current limitations and propose future directions, emphasizing the need for the integration of the pathological and physiological characteristics of specific mucosa with artificial intelligence (AI) platforms to develop intelligent and personalized delivery platforms with “spatiotemporal adaptive” capabilities.